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Significance of the tissue kallikrein promoter and transform-
ing growth factor-b1 polymorphisms with renal progression in
children with vesicoureteral reflux.
Background. Tissue kallikrein regulates blood circulation.
Low urinary kallikrein excretion was associated with hyper-
tension and renal disease in blacks. The polymorphic KLK1
promoter includes −130 GN coupled with multiple single base
substitutions. The −130 G12 allele in the KLK1 promoter was
associated with lower transcriptional activity and hyperten-
sive end-stage renal disease (ESRD) in blacks. Transforming
growth factor-b1 (TGF-b1) regulates matrix production, and
induces fibrosis in a variety of tissues. High circulating TGF-
b1 levels mediating renal fibrosis and loss of function in trans-
genic mice. The −509 T allele in the TGF-b1 promoter showed
marginally higher transcriptional activity, and was associated
with increased TGF-b1 production in humans. The aim of this
study was to investigate whether the tissue KLK1 promoter and
TGF-b1 polymorphism are involved in primary vesicoureteric
reflux (VUR) with renal progression in children.
Methods. Seventy-four primary VUR children were studied
with regular annual follow-up for more than 18 years, all of them
more than grade II (diagnosed by voiding cystourethroradiogra-
phy). All of them were born before 1984. Patients were classified
into two groups according to the renal function with progressive
deterioration or not. Patients with baseline creatinine clearance
(CCr) less than 25 mL/min were defined as having chronic renal
insufficiency (CRI). The TGF-b1 –509 T-C polymorphism was
analyzed by Bsu36I restriction fragment length polymorphism
(RFLP)-polymerase chain reaction (PCR). In KLK1 promoter,
the −130 GN length polymorphism and multiple single base sub-
stitutions were analyzed by electrophoresis of fluoresced PCR
products in sequencing gels, single strand conformation poly-
morphism (SSCP), allele-specific PCR, and DNA sequencing.
Patients’ TGF-b1 and KLK1 promoter polymorphisms were
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evaluated for association with VUR susceptibility and progres-
sion in Taiwanese children. Annual echocardiography study was
used to evaluate left ventricular mass index (LVMI).
Results. Four alleles were identified in the complex KLK1
promoter: A (−130 G10), B (−130 G2CG7), H (−130 G11), and
K (−130 G12). The polymorphic KLK1 promoter showed no
association with VUR susceptibility. However, the frequency
distribution of KLK1 promoter among VUR patients with or
without CRI (A, 50.0% and 67.5%; B, 17.9% and 8.3%; H,
14.3% and 18.3%; K, 17.9% and 5.8%, respectively) was sta-
tistically different (P = 0.008). Significantly higher K allele fre-
quency was present in primary VUR with CRI children, as it was
in the renal survival curve study. A significant increase of LVMI
was also found in the A allele group compared with the non-
A allele group of KLK1 promoter gene at the age of 18 years
old with renal progression. The TGF-b1 gene polymorphism
was determined, and we found significant over-representation
of the TT genotype in primary VUR patients with CRI com-
pared with normal renal function (P = 0.0035).
Conclusion. The K allele of KLK1 promoter and TT genotype
of TGF-b1 may be a genetic KLK1 −130 GN and −128 G-C,
and the susceptibility factor contributing to progressive renal
deterioration in Taiwanese primary VUR children.
Renal injury associated with the vesicoureteral reflux
(VUR) of urine that is infected, under high pressure,
or both, is a major cause of severe hypertension during
childhood and adolescence and of chronic renal insuffi-
ciency in patients less than 30 years of age. The inflam-
matory process caused by a pyelonephritis may result in
renal injury or scarring, which in turn may result in re-
nal insufficiency, renin-mediated hypertension, end-stage
renal disease (ESRD) [also termed reflux nephropathy
(RN)], reduced somatic growth, and morbidity during
pregnancy. Between 3.1% to 25% of children and 10%
to 15% of adults with ESRD have RN. Focal glomerular
sclerosis, a lesion found in patients with proteinuria and
RN, has been identified not only in scarred kidneys, but
is also seen in contralateral, unscarred kidneys without
VUR, which might suggest a humoral factor, or perhaps a
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hyperfiltration phenomenon. RN is one of the most fre-
quent causes of ESRD in children, adolescents, and young
adults, and is potentially preventable. However, pre-
vention will depend on early identification of patients
at risk—infants and young children after the first uri-
nary tract infection (UTI), and siblings of patients with
VUR—aggressive and effective treatment of UTI, mini-
mizing intravesical pressure, and education of patients,
parents, and physicians. Although the pathogenesis of
the disease is unknown, genetic variations may link its
susceptibility and progression. Tissue kallikrein (KLK1)
and transforming growth factor-b1 (TGF-b1) are the po-
tential candidate prognostic factors in the progression of
renal damage and development of ESRD. TGF-b1 is a
multifunctional cytokine that regulates cell growth, dif-
ferentiation, and matrix production. It is secreted by sev-
eral cell types and induces fibrosis in a variety of tissues,
including kidney, heart, and blood vessels [2]. Overpro-
duction of TGF-b1 has been linked to the sequel of pro-
gressive renal disease [3]. High circulating TGF-b1 levels
mediating renal fibrosis and loss of function have also
been demonstrated in transgenic mice [4]. Several poly-
morphisms in the TGF-b1 gene have been identified [5].
Among them, −509 T-C and R25P have been reported
to be associated with increased TGF-b1 production in
humans [6–8].
Kallikreins are serine proteases that have been im-
plicated in blood regulation by genetic and physiologic
studies [9]. The kallikrein gene family is clustered on chro-
mosome 19q13.3-q13.4 [10]. Among these genes, KLK1
encodes tissue kallikrein, the principal kinin-generating
enzyme found in the human kidney, pancreas, and saliva.
Tissue kallikrein processes low-molecular-weight kinino-
gen to produce the potent vasoactive kinin peptide [11].
Genetic factors causing a decrease of renal kallikrein
activity might contribute to the pathogenesis of hyper-
tension or associated renal complications [12, 13]. A
poly-guanine length polymorphism coupled with multi-
ple single-base substitutions has been identified in the
−121 to −131 promoter region of the KLK1 gene [14].
Functional analysis in human embryonic kidney 293 cells
suggests that different haplotype alleles contribute sig-
nificantly to the level of kallikrein expression [14]. An
association of 12 G allele with hypertensive ESRD in
blacks was established [15].
In this study, the implication of the TGF-b1 and KLK1
gene polymorphisms in the progression of VUR in Tai-
wanese children was analyzed.
METHODS
Patient population
From 1985 to 1990, a total of 74 patients aged 1 to 10
years old from different families were diagnosed as hav-
ing primary VUR more than grade II, in Taipei Veterans
General Hospital, and underwent continuous follow-up
until the present time. All patients were born before 1984.
VUR was diagnosed by voiding cystourethroradiography
(VCUG), and graded as I to V according to the classifi-
cation of Rollestion et al. Renal function was estimated
from creatinine clearance (CCr) or serum creatinine (Cr),
and compared with expected value for age. Patients with
baseline CCr less than 25 mL/min after age of 18 years old
were defined as having chronic renal insufficiency (CRI).
Hypertension was said to exist in children when diastolic
blood pressure (BP), measured with a cuff of an appropri-
ate size on more than one occasion on an upper extremity,
was >2 standard deviations (SD) above the mean dias-
tolic pressure for the patient’s age and sex. During the
follow-up period, 14 patients progressed to end-stage re-
nal disease (ESRD).
One hundred seventy patients with normal renal sono-
gram and without pyuria were included as control pa-
tients. All of them were students selected from National
Taiwan Normal University. All subjects gave consent to
the studies. Genomic DNA was isolated from peripheral
mononuclear cells, as previously described [16].
All patients (aged over 18 years) were required to give
a written informed consent to data collection, reporting,
and DNA analysis.
Polymerase chain reaction (PCR) amplification
and genotype analysis
Genomic DNA (100 ng) was used in a 25 lL PCR re-
action containing 10 mmol/L Tris, pH 8.3, 50 mmol/L
KCl, 0.1% Triton X-100, 0.2 mmol/L desoxynucleoside
triphosphate (dNTP), 10 pmol primers, and 1 U Taq
DNA polymerase (Promega, Madison, WI, USA). The
PCR was carried out for 35 cycles in a HyBaid thermal
cycler (OmniGene, Cambridge, MA, USA) with cycling
conditions at 94◦/30 seconds, 60◦/30 seconds, 72◦/30 sec-
onds. To genotype the KLK1 promoter polymorphism,
a 180-bp fragment was amplified using primers hKPM6
and 5′-fam-hKPM7 [14] (Fig. 1) with 1.0 mmol/L MgCl2.
Three lL of the amplified products were mixed with an
equal volume of 95% formamide buffer, and subjected to
single-strand conformation polymorphism (SSCP) anal-
ysis using GeneGel Excel gels as recommended by the
manufacturer (Pharmacia Biotech, Uppsala, Sweden).
The length of the amplified products was determined
by electrophoresis in a linear polyacrylamide gel on an
automated MegaBACE Analyzer (Molecular Dynam-
ics, division of Amersham Pharmacia Biotech). Different
genotypes can be distinguished by combined patterns of
SSCP (top part, ∗) and heteroduplex (bottom part, ∗∗)
(Fig. 1). Additionally, the polymorphism was analyzed
using allele-specific primers hKPMA and hKPMB and
the downstream hKPM7 primer [14](Fig. 1). The PCR
conditions were optimized to ensure that the mismatched
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Fig. 1. Genotype analysis of human tissue
kallikrein gene promoter polymorphism. Map
of the oligonucleotide primers for polymerase
chain reaction (PCR) (A). The promoter re-
gion is represented by gray rectangle and the
position of the polymorphic region (−121 ∼
−130) is shaded. Location of primers hKPM6,
hKPMA, hKPMB, and hKPM7 is indicated
with arrowheads. Electrophoresis of fluores-
cenced PCR products in linear polyacry-
lamide gels on an automated sequencer (B).
Electrophoresis of danatured PCR products
for SSCP and heteroduplex analyses (C).
Electrophoresis of B allele-specific PCR am-
plified products in 2.2% agarose gel (D). The
template genotypes in (B-D) are indicated by
AH, BB, AK, AB, AA, BK, AH, HH, BH,
and HK.
primer would not function as the perfect primer, such as
the 115-bp B allele specific products were only seen in
subjects with B allele (Fig. 1). Finally, alleles A (−130
G10), B (−130 G10 and –128 C), H (−130 G11), and K
(−130 G12) were established by cloning and sequencing.
To genotype the TGF-b1–509 T-C polymorphism,
an 808-bp fragment was amplified using forward
primer: 5′-CCCGGCTCCATTTCCAGGTG and reverse
primer: 5′-GGTCACCAGAGAAAGAGGAC [17] with
1.5 mmol/L MgCl2. Three lL of the amplified prod-
ucts were digested with Bsu36I restriction enzyme and
separated on 1.4% agarose gel. After ethidium bromide
staining, 617- and 191-bp fragments appeared on the poly-
morphic −509 C allele, whereas an 808-bp fragment ap-
peared on the common −509 T allele.
Statistical analysis
The allele frequency was calculated from the geno-
type frequency data by standard methods for codomi-
nant markers. The expected genotypic frequency under
random mating was computed, and chi-square test was
performed, for Hardy-Weinberg equilibrium [18]. The al-
lele association analysis was carried out using the relative
predispositional effect (RPE) technique [19] as described
[15]. A significant difference between cases and control
patients was defined as P < 0.05.
Survival curve until CRI was calculated by the Kaplan-
Meier life tables. Differences in survival between the
groups were tested by the log-rank test or multi-
regression analysis supported by logistics. Hazard ratios
and odds ratios with 95% confidence interval were calcu-
lated from the exponential in the regression model. All
P values were two-tailed.
RESULTS
Clinical features
The 74 patients from different families were diagnosed
with VUR. The mean follow-up time was more than
18 years. In all patients, the grades of VUR were more
than II. Fourteen patients progressed to ESRD dur-
ing follow-up. In all of them, the CCr was less than
the present 5 mL/min/1.73 m2. Six cases received renal
transplantation.
Association analysis of KLK1 promoter polymorphisms
with VUR and renal progression
The genotypes at KLK1 promoter of the 170 healthy
normal control patients were analyzed. Two loci, a length
locus at position −130 (G10, G11, and G12), and a G-C
substitution locus at position −128, were identified in
the complex KLK1 promoter. The four alleles, A (−130
G10), B (−130 G2CG7), H (−130 G11), and K (−130 G12)
generated 9 different genotypes, which can be readily
distinguished by combination of electrophoresis, SSCP,
heteroduplex, and allele-specific PCR analyses (Fig. 1).
For KLK1 promoter polymorphisms, we confirmed that
the genotype proportions fit the Hardy-Weinberg equi-
librium estimated by chi-square test. Of 340 control
chromosomes examined, the less common alleles are
35.0% for KLK1 B, H, and K all together. The genotype
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Table 1. Association analysis of KLK1 promoter polymorphisms in
VUR patients with or without progression to CRI
Locus Allele N %a N %b Allele P Locus total P
KLK1 A 14 (50.0) 81 (67.5) 0.26 0.008
B 5 (17.9) 10 (8.3) 0.06
H 4 (14.3) 22 (18.3) 0.62
K 5 (17.9) 7 (5.8) 0.008
Total 28 (100) 120 (100)
VUR, vesicoureteral reflux; CRI, chronic renal insufficiency.
A, G10; B, G2CG7; H, G11; K, G12.
aWith progression; bwithout progression.
M TC TC TT TC TC TT TC TC CC CCbp
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Fig. 2. Restriction analysis of transforming growth factor-b1 (TGF-b1)
–509 T-C polymorphism. The amplified 808-bp fragments were digested
with Bsu36I and separated in a 1.4% agarose gel. Lane M (HinfI digest
of pGEM4 DNA) is used for size markers. The template genotypes are
indicated by TC, TT, and CC.
distribution of the 74 VUR children was examined. Using
the RPE technique [19], the allele frequencies between
the 340 control chromosomes and 148 VUR chromo-
somes were compared. When the 28 VUR chromosomes
with CRI were analyzed for associations using the al-
lele frequencies calculated from 120 VUR chromosomes
without CRI, a significant allele association was observed
for the KLK1 locus (both K allele-specific P and total P =
0.008) (Table 1). Renal survival curves from appearance
of CRI in 14 children according to the KLK1 alleles show
significant difference with the allele (Fig. 3).
TGF b1(C/T) genotype and allele distribution with renal
progression in children with VUR
The TGF b1-509T-C is a biallelic restriction fragment
length polymorphism (RFLP) site that was readily de-
tected by Bsu 36I restriction analysis (Fig. 2). The dis-
tribution of the TGF b1(C/T) genotype in the control
group was TT in 50 (29.4%), TC in 93 (54.7%), and CC
in 27 (15.9%). The TGFb1 (C/T) genotype distribution is
in accordance with the Hardy-Weinberg equilibrium. In
children with VUR, the distribution of the TGFb1 (C/T)
genotype in children with progression to CRI was signif-
icantly different from that of the VUR children without
progression to CRI and healthy control patients (P =
0.015) (Table 2). In 28 patients with VUR, the T allele
was found more frequently than in VUR progressing to
CRI (0.88 vs. 0.62; P = 0.035) (Table 2).
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Fig. 3. Renal survival curves in vesicoureteral reflux (VUR) children
with progression to chronic renal insufficiency (CRI) by KLK1 gene
promoter polymorphism.
Table 2. TGF-b1 (T/C) genotype and allele distribution in healthy
Taiwanese control and children with VUR
Genotype Allele
TT TC CC T allele C allele
Control (N = 170) 50 93 27
Frequencies 0.29 0.55 0.16 0.57 0.43
VUR patients (N = 60) 24 27 9
Frequencies 0.32 0.53 0.15 0.62 0.38
VUR patients progress 11 2 1
to CRI (N = 14)a
Frequencies 0.74 0.19 0.07 0.86 0.14
Abbreviations are: VUR, vesicoureteral reflux; CRI, chronic renal insuffi-
ciency. The distribution of TGF-b1 (T/C) genotype and allele frequency was
significantly different when compared with control patients.
aP < 0.05 (contingency table method).
Table 3. Hazards ratios with 95% confidence interval for ACE
(TGF-b1) genotypes at presentation for progression to CRI in
patients with VUR
Variables Hazards ratio 95% CI P value
TGF-b1 genotype
TT vs. CC 0.387 0.211–0.628 0.0385
TT vs. TC 0.368 0.201–0.674 0.0377
CC vs. TC 0.384 0.221–0.670 0.007
Abbreviations are: VUR, vesicoureteral reflux; CRI, chronic renal insuffi-
ciency; ACE, angiotensin-converting enzyme.
Proportional hazards analysis showed significant dif-
ference in hazards for progression to CRI with the TGFb1
(TT) genotype in children with VUR (Table 3), as was the
case with the KLK1 (AA) genotype. All of the patients
who progressed to CRI with VUR were without hyper-
tension before progression to renal failure.
Fourteen of 74 children with VUR progressed to CRI.
According to TGFb1 (T/C) genotype, study in renal sur-
vival curves appear to reach significant difference among
TT, TC, and CC genotypes (P < 0.05, log-rank test)
(Fig. 4).
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Fig. 4. Renal survival curves in vesicoureteral reflux (VUR) children
with progression to chronic renal insufficiency (CRI) by transforming
growth factor-b1 (TGF-b1) gene promoter polymorphism.
Correlation between left ventricular mass progression
and KLK1 promoter polymorphisms with VUR
and renal progression
Left ventricular hypertrophy (LVH) is one of the risk
factors for the development of cardiac complications in
pediatric CRI patients. The size of the cardium is very
important for the life progress in pediatric CRI patients.
In respect to LVMI, during the 18 years of follow-up a
significant increase of LVMI was found in the A allele
group compared with the non-A allele group of KLK1
promoter gene (136 ± 28 vs. 108 ± 26 g/m2, P < 0.01)
at the age of 18 years old with renal progression. There
was no statistical difference between, with, and without
hypertension in KLK1 promoter polymorphism.
DISCUSSION
In the present study, polymorphic sites within the TGF-
b1 and KLK1 promoters were studied. Both polymor-
phisms examined were in Hardy-Weinberg equilibrium,
indicating random mating and random union of gametes
in the population sampled. The genotype frequencies are
therefore not influenced by evolutionary forces such as
mutation, migration, or natural selection. Within TGF-b1
gene, four other reported variations (−880 A-G, −800
G-A, R25P, and T263I) were not observed in the stud-
ied population (data not shown). It is possible that these
variations were not present in the founding population in
Chinese.
In our study, more TGF-b1 −509 T alleles were seen
in VUR chromosomes compared with control chromo-
somes (68.9% vs. 56.8%). Furthermore, more −509 T al-
leles were observed in VUR with progression to ESRD
chromosomes compared with VUR without progress to
ESRD (Table 2), with statistical significance. The −509 T
allele was reported to be associated with increased plasma
TGF-b1 concentration in humans [7], as well as with
marginally higher transcriptional activity in COS-1 cells
[20]. TGF-b1 regulates matrix production and induces fi-
brosis in a variety of tissues. Overproduction of TGF-b1
has been linked to the sequel of progressive renal disease
[3]. Our data suggest that higher TGF-b1 expression is
associated with the occurrence of renal progression in
children with VUR.
Low urinary kallikrein excretion was associated with
hypertension and renal disease. The complex KLK1 pro-
moter has four alleles in our studied group (Table 1), as
initially found in the Asian populations [14]. In the ge-
netic analysis of different alleles we observed allelic asso-
ciation between the K allele (12 G at position −130) and
ESRD when VUR patients without ESRD were used as
control patients. The K allele was reported to be associ-
ated with low renal kallikrein expression [14]. The results
suggest that K allele is a risk factor for development of
ESRD in Taiwanese VUR children.
LVH is an independent predictor of cardiovascular
mortality in ESRD patients. Autopsy studies showed de-
position of calcium and intermocytic fibrosis in hyper-
trophic heart of ESRD patients. This longitudinal study
also aimed to explore the correlation between left ven-
tricular mass progression and KLK1 promoter polymor-
phisms with VUR and renal progression. Our results
demonstrated that repeated echocardiogram performed
after 15 years’ follow-up showed significant difference
regarding the increasing LVMI in the A allele group at
18 years of age. However, there is no correlation with
hypertension. From the videodensitometry (VDT) in
vivo study, ESRD patients showed significantly higher
myocardial reflectance and dishomogeneity than hyper-
tensive patients. Hypertensive patients showed VDT
parameters similar to healthy control patients, in spite
of significantly higher septum thickness and ventricular
mass. Therefore, myocardial structure of ESRD patients
is quite peculiar. An A allele of KLK1 promoter poly-
morphism is only one of the contributing factors.
CONCLUSION
The K allele of the KLK1 promoter gene and the TT
genotype of TGF-b1 may have a role in the renal pro-
gression of parenchymal damage associated with primary
VUR in Taiwanese children. Whether medical or surgical
intervention may effectively ameliorate progression of
disease, and irrespective of patients, over-representation
of the TT genotype in primary VUR children needs to be
done in the future.
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